A$178.85
0.29% day before yesterday
Australia, Nov 21, 06:10 am CET
ISIN
AU000000CSL8
Symbol
CSL

CSL Stock price

A$178.85
-41.56 18.86% 1M
-63.54 26.22% 6M
-97.27 35.23% YTD
-89.57 33.37% 1Y
-104.76 36.94% 3Y
-117.10 39.57% 5Y
+92.04 106.03% 10Y
+168.86 1,689.91% 20Y
Australia, Closing price Fri, Nov 21 2025
+0.51 0.29%
ISIN
AU000000CSL8
Symbol
CSL
Industry

New AI Insights on CSL Insights AI Insights on CSL

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?

Key metrics

Basic
Market capitalization
A$86.5b
Enterprise Value
A$101.0b
Net debt
A$14.5b
Cash
A$3.3b
Shares outstanding
484.2m
Valuation (TTM | estimate)
P/E
18.7 | 16.3
P/S
3.6 | 3.4
EV/Sales
4.2 | 4.0
EV/FCF
25.4
P/B
2.9
Dividends
DPS
A$4.52
Yield 1Y | 5Y
2.5% | 1.4%
Growth 1Y | 5Y
13.8% | 9.0%
Payout 1Y | 3Y
47.3% | 48.4%
Increased
4 Years
Financials (TTM | estimate)
Revenue
A$24.1b | A$25.1b
EBITDA
A$7.9b | A$8.8b
EBIT
A$6.4b | A$7.7b
Net Income
A$4.7b | A$5.3b
Free Cash Flow
A$4.0b
Growth (TTM | estimate)
Revenue
5.1% | 4.2%
EBITDA
7.8% | 24.7%
EBIT
7.7% | 20.8%
Net Income
13.6% | 14.5%
Free Cash Flow
70.2%
Margin (TTM | estimate)
Gross
51.9%
EBITDA
32.9% | 35.2%
EBIT
26.4%
Net
19.3% | 21.2%
Free Cash Flow
16.5%
Financial Health
Equity Ratio
49.1%
Return on Equity
15.5%
ROCE
11.9%
ROIC
10.4%
Debt/Equity
0.6
More
EPS
A$9.6
FCF per Share
A$8.2
Short interest
-
Employees
33k
Rev per Employee
A$740.0k
Show more

Is CSL a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.

CSL Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a CSL forecast:

15x Buy
75%
5x Hold
25%

Analyst Opinions

20 Analysts have issued a CSL forecast:

Buy
75%
Hold
25%

Financial data from CSL

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
24,106 24,106
5% 5%
100%
- Direct Costs 11,588 11,588
5% 5%
48%
12,518 12,518
5% 5%
52%
- Selling and Administrative Expenses 4,053 4,053
8% 8%
17%
- Research and Development Expense 2,106 2,106
5% 5%
9%
7,935 7,935
8% 8%
33%
- Depreciation and Amortization 1,576 1,576
8% 8%
7%
EBIT (Operating Income) EBIT 6,359 6,359
8% 8%
26%
Net Profit 4,651 4,651
14% 14%
19%

In millions AUD.

Don't miss a Thing! We will send you all news about CSL directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Paul McKenzie
Employees 32,698
Founded 1961
Website www.csl.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today